A multi-center, randomized, double-blind, double-dummy, parallel-group dose-finding study to evaluate the change in HbA1c after 12 weeks monotherapy with seven doses of LIK066 compared with placebo or sitagliptin in patients with type 2 diabetes
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 12 Apr 2016
At a glance
- Drugs LIK 066 (Primary) ; Sitagliptin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 31 Aug 2018 Biomarkers information updated
- 02 Apr 2014 According to the ClinicalTrials.gov record, status changed from recruiting to withdrawn prior to recruitment.
- 03 Aug 2013 New source identified and integrated (European Clinical Trials Database: EudraCT2012-005793-63).